Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/6/2019
SIETES contiene 92761 citas

 
 
<< anterior 21 a 40 de 157 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus SW, Ribas S, KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32. [Ref.ID 99312]
22. Cita con resumen
Loeb S, Folkvaljon Y, Lambe M, Robinson D, Gamo H, Ingvar C, Stattin P. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015;313:2449-55. [Ref.ID 99307]
23. Cita con resumen
Anónimo. Nivolumab (Opdivo) for metastatic melanoma and metastatic NSCLC. Med Lett Drugs Ther 2015;57:85-7. [Ref.ID 99225]
24. Cita con resumen
Wu S, Han J, Feskanich D, Cho E, Stampfer MJ, Willett WC, Qureshi AA. Citrus consumption and risk of cutaneous malignant melanoma. Journal of Clinical Oncology 2015;33:2500-8. [Ref.ID 99223]
25. Cita con resumen
Postow MA, Chesney J, Pavick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17. [Ref.ID 99140]
26. Cita con resumen
Herman AO. Vitamin B3 helps prevent non-melanoma skin cancers in high-risk adults. Journal Watch 2015:15 de mayo. [Ref.ID 99081]
27. Cita con resumen
Anónimo. New cancer drugs expected to drive pharmaceutical growth. DIA Daily 2015:29 de abril. [Ref.ID 99023]
28. Cita con resumen
Anónimo. Ipilimumab et mélanome métastasé ou inopérable. Prescrire 2015;35:95. [Ref.ID 98911]
29. Cita con resumen
Anónimo. FDA expands approved use of Opdivo to treat lung cancer. U.S. Food and Drug Administration 2015:4 de marzo. [Ref.ID 98865]
30. Cita con resumen
Anónimo. FDA approves first immune-based lung cancer treatment. DIA Daily 2015:5 de marzo. [Ref.ID 98830]
32. Cita con resumen
Anónimo. Dabrafénib. Mélanome métastasé: me-too du vémurafénib. Prescrire 2014;34:889-92. [Ref.ID 98468]
33. Cita con resumen
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu W-J, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17. [Ref.ID 98106]
35. Cita con resumen
Anónimo. FDA approves new immunotherapy for melanoma. DIA Daily 2014:5 de septiembre. [Ref.ID 97863]
36. Cita con resumen
Fulco I, Miot S, Haug MD, Barbero A, Wixmerten A, Feliciano S, Wolf F, Jundt G, Marsano A, Farhadi J, Heberer M, Jakob M, Schaefer DJ, Martin I. Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial. Lancet 2014;384:337-46. [Ref.ID 97833]
37. Cita con resumen
Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajweski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014;311:2397-405. [Ref.ID 97705]
38.Tiene citas relacionadas
Shlipak MG, Coresh J, Gansevoort RT. Cystatin C versus creatinine for kidney function-based risk. The authors reply. N Engl J Med 2013;369:2459. [Ref.ID 96682]
39.Tiene citas relacionadas
Vandecasteele SJ, De Vriese AS. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458-9. [Ref.ID 96681]
40.Tiene citas relacionadas Cita con resumen
Cherney D, Maahs DM. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458. [Ref.ID 96680]
Seleccionar todas
 
<< anterior 21 a 40 de 157 siguiente >>